GleamWall
中文EN

ALKS Alkermes plc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1520262 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY15.3%
TTM net income YoY-100.1%
TTM EPS YoY-100.5%
Revenue 3-yr CAGR3.3%
Net income 3-yr CAGR—

Margins

Gross margin82.9%
Operating margin3.7%
Net margin-0.0%
FCF margin13.0%
EBITDA margin8.3%

Returns

ROE-0.0%
ROA-0.0%
ROIC (approx.)1.7%
Asset turnover0.52x

Leverage & solvency

Liabilities / assets58.0%
Debt / equity0.80x
Current ratio2.42x
Interest coverage0.74x

Cash quality & payout

Operating cash flow / net income-692.27x
Accruals ratio-7.2%
Payout ratio—
Capex / revenue0.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$480.13M$496.01M$392.91M$384.55M$394.19M$390.66M$306.51M$429.99M
Cost of revenue$94.22M$98.11M$61.58M$46.21M$51.59M$49.46M$49.20M$62.12M
Gross profit$385.91M$397.90M$331.33M$338.34M$342.59M$341.20M$257.31M$367.87M
R&D expense$121.12M$112.92M$103.34M$93.04M$81.74M$77.37M$71.82M$58.17M
SG&A expense$208.50M$217.62M$264.59M$187.20M$171.77M$170.85M$171.70M$146.99M
Operating income$36.02M$18.35M-$48.28M$58.10M$89.08M$92.98M$13.79M$162.69M
Interest expense$27.55M$25.93M$20.89M$12.28M$0$0$0$4.65M
Pretax income$14.74M-$1.88M-$61.93M$60.38M$100.75M$104.84M$25.49M$169.89M
Income tax-$1.55M-$2.38M$4.55M$11.04M$17.98M$17.74M$3.02M$24.15M
Net income$16.29M$501,000-$66.48M$49.34M$82.76M$87.10M$22.46M$146.50M
EBITDA$63.18M$48.63M-$28.85M$61.95M$97.16M$100.80M$21.21M$169.53M
EPS (basic)0.100.00-0.40—0.500.530.14—
EPS (diluted)0.090.00-0.40—0.490.520.13—
Weighted avg. shares (diluted)176.37M173.48M166.20M—168.51M168.36M168.74M—
Balance sheet
Cash & equivalents$631.31M$511.53M$351.55M$388.57M$616.45M$521.20M$399.81M$291.15M
Short-term investments$124.15M$145.05M$160.31M$199.65M$494.67M$494.54M$484.21M$460.52M
Receivables$459.09M$456.48M$407.63M$334.02M$354.39M$354.91M$318.70M$384.53M
Inventory$261.10M$298.96M$336.70M$196.62M$191.00M$191.92M$183.44M$182.89M
Current assets$1.58B$1.52B$1.36B$1.93B$1.74B$1.64B$1.48B$1.42B
PP&E, net$215.02M$218.28M$220.59M$221.72M$246.98M$239.40M$233.92M$227.56M
Goodwill$592.52M$594.27M$596.03M$83.03M———$83.03M
Intangibles$1.74B$1.76B$1.78B$815,000———$890,000
Total assets$4.44B$4.39B$4.26B$2.49B$2.33B$2.25B$2.08B$2.06B
Current liabilities$651.93M$662.09M$599.50M$543.44M$474.36M$505.96M$443.73M$465.20M
Short-term debt$26.50M$26.50M$26.50M$0————
Long-term debt$1.47B$1.48B$1.48B$0————
Total debt$1.50B$1.50B$1.51B$0————
Total liabilities$2.57B$2.58B$2.51B$667.70M$596.08M$628.23M$570.39M$590.59M
Shareholders' equity$1.86B$1.81B$1.75B$1.82B$1.73B$1.62B$1.51B$1.46B
Net debt$866.42M$991.58M$1.16B-$388.57M————
Shares outstanding168.03M167.54M166.46M165.61M165.10M165.05M164.85M162.18M
Cash flow statement
Operating cash flow$93.48M$145.18M-$165.74M$170.07M$101.67M$150.20M$98.81M$190.40M
Capital expenditure$3.40M$8.15M$4.09M-$20,000$17.31M$13.02M$10.11M$9.77M
Free cash flow$90.08M$137.04M-$169.83M$170.09M$84.36M$137.19M$88.70M$180.62M
Investing cash flow$19.99M-$2.41M-$2.08B$322.35M-$6.74M-$29.21M$9.10M-$13.88M
Financing cash flow$6.32M$17.20M$1.47B$10.91M$315,000$405,000$747,000-$281.67M
Depreciation & amortization$27.16M$30.28M$19.43M$3.85M$8.08M$7.82M$7.42M$6.85M
Stock-based compensation$26.75M$31.14M$36.33M$26.27M$24.66M$24.97M$22.81M$20.75M
Share buybacks$0$0$27.70M—$0——$1,000

Free plan shows the latest 8 periods; Pro shows all 65 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.